• Explore /
  • Poster
  • / Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease: Results from the MD Anderson INTERCEPT Program.

Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease: Results from the MD Anderson INTERCEPT Program.

Abstract Poster

Authors

null

Andrew Jared Pellatt

MD Anderson Hematology/Oncology Fellowship, Houston, TX

Andrew Jared Pellatt , Giulia Maddalena , Madhulika Eluri , Christine Megerdichian Parseghian , Kathryn Aziz , Kristin Alfaro , Robert J. Kell , Alisha Heather Bent , Ryan W Huey , Abhineet Uppal , Tsuyoshi Konishi , Michael J. Overman , Maria Pia Morelli , Jason Willis , John Paul Y.C. Shen , Kanwal Pratap Singh Raghav , Timothy E. Newhook , Van K. Morris II, Arvind Dasari , Scott Kopetz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 196)

DOI

10.1200/JCO.2024.42.3_suppl.196

Abstract #

196

Poster Bd #

M4

Abstract Disclosures

Similar Posters

First Author: Yoshiaki Nakamura

First Author: Eiji Oki

First Author: Di Cao

First Author: Ippokratis Messaritakis